GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » ARYx Therapeutics Inc (OTCPK:ARYX) » Definitions » Market Cap

ARYx Therapeutics (ARYx Therapeutics) Market Cap : $0.00 Mil (As of May. 05, 2024)


View and export this data going back to 2007. Start your Free Trial

What is ARYx Therapeutics Market Cap?

Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). ARYx Therapeutics's share price for the quarter that ended in Sep. 2010 was $0.4. ARYx Therapeutics's Shares Outstanding (EOP) for the quarter that ended in Sep. 2010 was 33.46 Mil. Therefore, ARYx Therapeutics's market cap for the quarter that ended in Sep. 2010 was $13.38 Mil.

ARYx Therapeutics's quarterly market cap declined from Mar. 2010 ($29.11 Mil) to Jun. 2010 ($14.05 Mil) and declined from Jun. 2010 ($14.05 Mil) to Sep. 2010 ($13.38 Mil).

ARYx Therapeutics's annual market cap declined from Dec. 2007 ($136.82 Mil) to Dec. 2008 ($79.38 Mil) but then increased from Dec. 2008 ($79.38 Mil) to Dec. 2009 ($89.99 Mil).

Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. ARYx Therapeutics's Enterprise Value for Today is $0.00 Mil.


ARYx Therapeutics Market Cap Historical Data

The historical data trend for ARYx Therapeutics's Market Cap can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ARYx Therapeutics Market Cap Chart

ARYx Therapeutics Annual Data
Trend Dec03 Dec04 Dec05 Dec06 Dec07 Dec08 Dec09
Market Cap
Get a 7-Day Free Trial - - 136.82 79.38 89.99

ARYx Therapeutics Quarterly Data
Dec05 Mar06 Jun06 Sep06 Dec06 Mar07 Jun07 Sep07 Dec07 Mar08 Jun08 Sep08 Dec08 Mar09 Jun09 Sep09 Dec09 Mar10 Jun10 Sep10
Market Cap Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 85.99 89.99 29.11 14.05 13.38

Competitive Comparison of ARYx Therapeutics's Market Cap

For the Drug Manufacturers - Specialty & Generic subindustry, ARYx Therapeutics's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


ARYx Therapeutics's Market Cap Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, ARYx Therapeutics's Market Cap distribution charts can be found below:

* The bar in red indicates where ARYx Therapeutics's Market Cap falls into.



ARYx Therapeutics Market Cap Calculation

Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.

ARYx Therapeutics's Market Cap for the fiscal year that ended in Dec. 2009 is calculated as

Market Cap (A: Dec. 2009 )=Share Price (A: Dec. 2009 )*Shares Outstanding (EOP) (A: Dec. 2009 )
=$3.21*28.0342
=$89.99

ARYx Therapeutics's Market Cap for the quarter that ended in Sep. 2010 is calculated as

Market Cap (Q: Sep. 2010 )=Share Price (Q: Sep. 2010 )*Shares Outstanding (EOP) (Q: Sep. 2010 )
=$0.4*33.462
=$13.38

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


ARYx Therapeutics  (OTCPK:ARYX) Market Cap Explanation

Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the company’s debt. The real price you pay is the Enterprise Value.

Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.


ARYx Therapeutics Market Cap Related Terms

Thank you for viewing the detailed overview of ARYx Therapeutics's Market Cap provided by GuruFocus.com. Please click on the following links to see related term pages.


ARYx Therapeutics (ARYx Therapeutics) Business Description

Traded in Other Exchanges
N/A
Address
6300 Dumbarton Circle, Fremont, CA, USA, 94555
ARYx Therapeutics Inc is a biopharmaceutical company focused on developing a portfolio of internally discovered product candidates designed to eliminate known safety issues associated with well-established, commercially successful drugs.
Executives
Newhall Charles W Iii 10 percent owner 1119 ST PAUL ST, BALTIMORE MD 21202
C Richard Kramlich 10 percent owner 1954 GREENSPRING DRIVE, SUITE 600, TIMONIUM MD 21093
Ryan D Drant 10 percent owner 1119 ST PAUL STREET, BALTIMORE MD 21202
Krishna Kittu Kolluri 10 percent owner
New Enterprise Associates 12, Limited Partnership 10 percent owner 1119 ST. PAUL STREET, BALTIMORE MD 21202
Nea Partners 12, Limited Partnership 10 percent owner 1119 ST. PAUL STREET, BALTIMORE MD 21202
Nea 12 Gp, Llc 10 percent owner 1119 ST. PAUL STREET, BALTIMORE MD 21202
Mark W Perry 10 percent owner
Patrick J Kerins 10 percent owner
Forest Baskett 10 percent owner
Growth Equity Opportunities Fund, Llc 10 percent owner 1119 ST. PAUL STREET, BALTIMORE MD 21202
Peter J Barris 10 percent owner 1119 ST PAUL STREET, BALTIMORE MD 21202
M James Barrett 10 percent owner 1119 ST PAUL STREET, BALTIMORE MD 21202
Scott D Sandell 10 percent owner
Nicholas Galakatos 10 percent owner THE JOHN HANCOCK TOWER, 200 CLARENDON STREET, 54TH FLOOR, BOSTON MA 02116

ARYx Therapeutics (ARYx Therapeutics) Headlines

No Headlines